O
Oneel Patel
Researcher at University of Melbourne
Publications - 45
Citations - 1030
Oneel Patel is an academic researcher from University of Melbourne. The author has contributed to research in topics: Gastrin-releasing peptide & Gastrin. The author has an hindex of 16, co-authored 45 publications receiving 851 citations.
Papers
More filters
Journal ArticleDOI
Gastrin-releasing peptide and cancer.
TL;DR: The detection of GRP and the GRP receptor in small cell lung carcinoma (SCLC), and the demonstration that anti-GRP antibodies inhibited proliferation in SCLC cell lines, established GRP as the prototypical autocrine growth factor.
Journal ArticleDOI
The Role of Hypoxia-Inducible Factor 1α in Determining the Properties of Castrate-Resistant Prostate Cancers
Weranja Ranasinghe,Lin Xiao,Suzana Kovac,Mike Chang,Carine Michiels,Damien M Bolton,Arthur Shulkes,Graham S. Baldwin,Oneel Patel +8 more
TL;DR: HIF1 α is likely to contribute to metastasis and chemo-resistance of CRPC and targeted reduction of HIF1α may increase the responsiveness of CR PCs to chemotherapy.
Journal ArticleDOI
Gastrin‐releasing peptide: Different forms, different functions
TL;DR: Over the last decade, nonamidated peptides derived from proGRP, such as the glycine‐extended form GRP18‐28 and recombinant and synthetic fragments from pro GRP31‐125, have been shown to be biologically active in a range of tissues and in cancer cell lines.
Journal ArticleDOI
FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine.
TL;DR: These results implicate PAK1 as a regulator of pancreatic cancer cell growth and survival and combined with cytotoxic chemotherapy deserves further study as a novel therapeutic approach to Pancreatic cancer treatment.
Journal ArticleDOI
HIF1α Expression under Normoxia in Prostate Cancer— Which Pathways to Target?
Weranja Ranasinghe,Graham S. Baldwin,Damien M Bolton,Arthur Shulkes,Joseph Ischia,Oneel Patel +5 more
TL;DR: There is an urgent need to identify the cause of Hif1α over expression in castrate resistant prostate cancer cells and tumors to guide the choice of HIF inhibitors (transcription or translation based) that are best suited for treating castrateresistant prostate cancer.